PRAX241220P110000
- 40.50
- 0.000.00%
Praxis Precision Medicines Newsroom
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $120
Praxis Precision Med Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
Praxis Precision Medicine Analyst Ratings
Jefferies Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $305
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $270
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $270
Piper Sandler Gives a Buy Rating to Praxis Precision Medicines (PRAX)
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $114 to $120
Praxis Precision Medicines: Strong Buy Rating Amid Potential Upside and Robust Pipeline Despite Operational Challenges
HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $120 Price Target
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $114 to $170
Praxis Precision Medicine Analyst Ratings
Wedbush Raises Praxis Precision Medicines Price Target to $57 From $51, Maintains Neutral Rating
Optimistic Buy Rating for Praxis Precision Medicines Amid Strategic Pipeline Advancements and Long-term Growth Potential
Praxis Precision Med Is Maintained at Outperform by Oppenheimer
Praxis Precision Medicine Analyst Ratings
Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $163
Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $143
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $270
Truist Financial Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating